Epigenetic regulation in myelodysplastic syndromes: Implications for therapy

Expert Opinion on Investigational Drugs

Volumn 20, Issue 4, 2011, Pages 465-493

  Vigna, Ernesto ^a   Recchia, Anna Grazia ^a   Madeo, Antonio ^a   Gentile, Massimo ^a   Bossio, Sabrina ^a   Mazzone, Carla ^a   Lucia, Eugenio ^a   Morabito, Lucio ^b   Gigliotti, Vincenzo ^a   Stefano, Laura De ^a   Caruso, Nadia ^a   Servillo, Pasquale ^a   Franzese, Stefania ^a   Fimognari, Filippo ^a   Bisconte, Maria Grazia ^a   Gentile, Carlo ^a   Morabito, Fortunato ^a  

^a Azienda Ospedaliera di Cosenza   (Italy)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

DNA methylation; epigenetics; histone modification; miRNA; myelodysplastic syndrome; therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BORTEZOMIB; DEPSIPEPTIDE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; GEMTUZUMAB OZOGAMYCIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; LENALIDOMIDE; MG 98; MICRORNA; MOCETINOSTAT; N PHTHALOYLTRYPTOPHAN; PANOBINOSTAT; RETINOIC ACID; ROMIDEPSIN; SGI 110; THALIDOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BLEEDING; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN HEMORRHAGE; CANCER INHIBITION; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; COLITIS; CONSTIPATION; CONTINUOUS INFUSION; CPG ISLAND; CYTOPENIA; DIARRHEA; DNA METHYLATION; DNA REPLICATION; DNA SEQUENCE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMBRYONIC STEM CELL; EPIGENETICS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENE SILENCING; GRANULOCYTOPENIA; GROWTH INHIBITION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HISTONE MODIFICATION; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY FAILURE; LARYNX EDEMA; LETHARGY; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; ORAL MUCOSAL PETECHIA; OVERALL SURVIVAL; PANCYTOPENIA; PATHOPHYSIOLOGY; PERIPHERAL CYTOPENIA; PETECHIA; PNEUMONIA; PROMOTER REGION; PROTEIN PROCESSING; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOCIAL SUPPORT; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOSIS; TRANSCRIPTION REGULATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES;

EID: 79952650654     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.559164     Document Type: Review

References (173)

1. Nimer SD. Myelodysplastic syndromes. Blood 2008;111:4841-51
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99 (Pubitemid 12073508)
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88 (Pubitemid 27132124)
4. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10 (Pubitemid 47315575)
5. Li X, Bryant CE, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 2004;80:140-5 (Pubitemid 39201567)
6. Bianchi E, Rogge L. Dissecting oncogenes and tyrosine kinases in AML cells. MedGenMed 2003;5:10
7. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science 2003;301:798-802 (Pubitemid 36962612)
8. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92 (Pubitemid 46273572)
10. Meshorer E, Misteli T. Chromatin in pluripotent embryonic stem cells and differentiation. Nat Rev Mol Cell Biol 2006;7:540-6 (Pubitemid 44036459)
11. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447:425-32 (Pubitemid 46816749)
12. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010;11:607-20
13. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 2007;26:6697-714 (Pubitemid 47585096)
14. Rush LJ, Plass C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett 2002;185:1-12 (Pubitemid 34876527)
15. Ji H, Ehrlich LI, Seita J, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010;467:338-42
16. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006;174:341-8 (Pubitemid 43235307)
17. Biancotto C, Frige G, Minucci S. Histone modification therapy of cancer. Adv Genet 2010;70:341-86
18. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5 (Pubitemid 30038513)
19. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10:295-304
20. Zhan M. Genomic studies to explore self-renewal and differentiation properties of embryonic stem cells. Front Biosci 2008;13:276-83 (Pubitemid 351594777)
21. Cheng LC, Tavazoie M, Doetsch F. Stem cells: from epigenetics to microRNAs. Neuron 2005;46:363-7
22. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996;122:135-40 (Pubitemid 26076883)
23. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385-95 (Pubitemid 351377805)
24. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-25
25. Hopfer O, Komor M, Koehler IS, et al. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. Exp Hematol 2007;35:712-23 (Pubitemid 46628726)
26. Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23-32
27. Grovdal M, Khan R, Aggerholm A, et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 2007;13:7107-12 (Pubitemid 350276895)
28. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764-73
29. Figueroa ME, Melnick A, Greally JM. Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. Methods Mol Biol 2009;538:395-407
30. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448-58
31. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007;138:3-11 (Pubitemid 46889779)
32. Hess CJ, Errami A, Berkhof J, et al. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 2008;49:1132-41 (Pubitemid 351943260)
33. Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008;112:2013-16
34. Agrawal S, Hofmann WK, Tidow N, et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007;109:3895-905 (Pubitemid 46641742)
35. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15 (INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res 2005;29:653-9 (Pubitemid 40603565)
36. Benetatos L, Hatzimichael E, Dasoula A, et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 2010;34:148-53
37. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40 (Pubitemid 34525728)
38. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-64
39. Fenrick R, Hiebert SW. Role of histone deacetylases in acute leukemia. J Cell Biochem Suppl 1998;30-31:194-202 (Pubitemid 29028741)
40. Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005;84(Suppl 1):61-6
41. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-9 (Pubitemid 39166498)
42. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-91 (Pubitemid 47477265)
43. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9
44. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol 2009;21:470-9
45. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010;16:49-58
46. Hussein K, Theophile K, Busche G, et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res 2010;34:328-34
47. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17
48. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9
49. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9 (Pubitemid 351550859)
50. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435-43 (Pubitemid 43832188)
51. Saito Y, Friedman JM, Chihara Y, et al. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009;379:726-31
52. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-9 (Pubitemid 46383366)
53. Qiu X, Hother C, Ralfkiaer UM, et al. Equitoxic doses of 5-azacytidine and 5-aza-2′deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One 2010;5: published online 29 September 2010, doi:10.1371/journal.pone.0012994
54. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006;5:2220-2 (Pubitemid 44546557)
55. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004;18:809-16 (Pubitemid 38500200)
56. Estey EH. Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Semin Hematol 1995;32:132-51
57. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer 2001;92:1059-73 (Pubitemid 32861652)
58. Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic leukemia working party of the European group for blood and marrow transplantation. Bone Marrow Transplant 1998;21:255-61 (Pubitemid 28052228)
59. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004;104:1616-23 (Pubitemid 39202266)
60. Kroger N, Schetelig J, Zabelina T, et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001;28:643-7 (Pubitemid 33014597)
61. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006;91:667-70 (Pubitemid 43799466)
62. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007;21:1436-41 (Pubitemid 46965284)
63. Anargyrou K, Vassilakopoulos TP, Angelopoulou MK, Terpos E. Incorporating novel agents in the treatment of myelodysplastic syndromes. Leuk Res 2010;34:6-17
64. Oki Y, Aoki E, Issa JP. Decitabine-bedside to bench. Crit Rev Oncol Hematol 2007;61:140-52 (Pubitemid 46073782)
65. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964;20:202-3
66. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93 (Pubitemid 10117303)
67. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology 1974;30:405-22
68. Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983;84:202-11
69. Friedman S. The inhibition of DNA (cytosine-5)methylases by 5-azacytidine. The effect of azacytosine-containing DNA. Mol Pharmacol 1981;19:314-20
70. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-801
71. Saiki JH, Bodey GP, Hewlett JS, et al. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology group study. Cancer 1981;47:1739-42 (Pubitemid 11145824)
72. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′- deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985;30:277-86 (Pubitemid 17207209)
73. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):21-9 (Pubitemid 23184796)
74. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-903 (Pubitemid 46630737)
75. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
76. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9
77. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer 1991;64:144-8
78. Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1981;5:453-62 (Pubitemid 12252112)
79. de Lima M, Ravandi F, Shahjahan M, et al. Long-term follow-up of a Phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 2003;97:1242-7 (Pubitemid 36237310)
80. Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997;11:1617-20 (Pubitemid 27458597)
81. Petti MC, Mandelli F, Zagonel V, et al. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993;7(Suppl 1):36-41 (Pubitemid 23184798)
82. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993;7(Suppl 1):51-60 (Pubitemid 23184801)
83. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11(Suppl 1):S19-23
84. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62 (Pubitemid 30123770)
85. Lubbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001;114:349-57 (Pubitemid 32762234)
86. Sigalotti L, Altomonte M, Colizzi F, et al. 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 2003;101:4644-6; discussion 4645-6
87. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 2006;106:1794-803
88. Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006;106:1099-109
89. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133-7 (Pubitemid 46435392)
90. Wijermans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with Intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukaemia and German MDS study groups. Blood (ASH Annual Meeting Abstracts): 2008;112
91. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7 (Pubitemid 46053042)
92. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-6
93. Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112:981-9
94. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9:809-24 (Pubitemid 41131680)
95. Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem 2003;278:27586-92 (Pubitemid 36899944)
96. Milutinovic S, D'Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007;28:560-71 (Pubitemid 46523352)
97. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005;104:101-9 (Pubitemid 40847757)
98. Kouraklis G, Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anticancer Agents 2002;2:477-84 (Pubitemid 34649886)
99. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int J Biochem Cell Biol 2007;39:1388-405 (Pubitemid 47031032)
100. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-22 (Pubitemid 46218694)
101. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109:2781-90 (Pubitemid 46482071)
102. Nakajima H, Kim YB, Terano H, et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241:126-33 (Pubitemid 28366586)
103. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105:959-67 (Pubitemid 40170861)
104. Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14:826-32 (Pubitemid 351231166)
105. Siegel D, Hussein M, Belani C, et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009;2:3
106. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76 (Pubitemid 40223701)
107. Giles F, Fischer T, Cortes J, et al. A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-35 (Pubitemid 44297814)
108. Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. ASH Annual Meeting Abstracts. Blood 2008;112:958
109. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7 (Pubitemid 29036293)
110. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9 (Pubitemid 28269714)
111. Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control 2008;15(Suppl):40-9
112. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9
113. Silverman LR, Verma A, Odchimar-Reissig R, et al. A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium. ASH Annual Meeting Abstracts. Blood 2008;112:3656
114. Kuendgen A, Bug G, Ottmann OG, et al. Treatment of Poor Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia with a Combination of 5-Azacytidine and Valproic Acid. ASH Annual Meeting Abstracts. Blood 2008;112:3639
115. Issa J-P, Castoro R, Ravandi-Kashani F, et al. Randomized Phase II study of combined epigenetic therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML. ASH Annual Meeting Abstracts. Blood 2008;112:228
116. Garcia-Manero G, Yang AS, Klimek V, et al. Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). ASH Annual Meeting Abstracts. Blood 2007;110:444
117. Ravandi F, Faderl S, Thomas D, et al. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. ASH Annual Meeting Abstracts. Blood 2007;110:897
118. Gao S, Mobley A, Miller C, et al. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res 2008;32:771-80 (Pubitemid 351323931)
119. Gore SD, Jiemjit A, Silverman LB, et al. Combined Methyltransferase/ Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage. ASH Annual Meeting Abstracts. Blood 2006;108:517
120. Candelaria M, Herrera A, Labardini J, et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol 2010: published online 5 October 2010, doi: 10.1007/s00277-010-1090-
121. Raffoux E, de Labarthe A, Cras A, et al. Epigenetic Therapy with 5-Azacitidine Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study. ASH Annual Meeting Abstracts. Blood 2008;112:763
122. Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009;15:5002-50077
123. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38 (Pubitemid 38030301)
124. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250-7
125. National Cancer Institute, Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT00818649) Bethesda, MD: clinicaltrials.gov, 2009. Available from: http://clinicaltrials. gov/ct2/show/NCT00818649?term=NCT00818649&rank=1 [Last accessed 7 February 1011]
126. Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia 2006;20:2093-101
127. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008;49:2141-7
128. Borthakur G, Estrov Z, Garcia-Manero G, et al. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. ASH Annual Meeting Abstracts. Blood 2008;112:2985
129. Raza A, Mehdi M, Mumtaz M, et al. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008;113:1596-604
130. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010;28:2253-8
131. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409 (Pubitemid 36395260)
132. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009;23:1019-28
133. Cornacchia E, Golbus J, Maybaum J, et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988;140:2197-200 (Pubitemid 18098475)
134. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003;48:746-56 (Pubitemid 36302012)
135. Singh N, Duenas-Gonzalez A, Lyko F, Medina-Franco JL. Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem 2009;4:792-9
136. Lavelle D, Saunthararajah Y, Vaitkus K, et al. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Transl Med 2010;8:92
137. Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-Aza-2′- deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 2010;9:1443-50
138. Scholl J, Joshi-Hangal R, Inloes R, et al. SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation. ASH Annual Meeting Abstracts. Blood 2010;116:1872
139. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65:6305-11 (Pubitemid 40994416)
140. Metivier R, Gallais R, Tiffoche C, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008;452:45-50 (Pubitemid 351355084)
141. Siedlecki P, Zielenkiewicz P. Mammalian DNA methyltransferases. Acta Biochim Pol 2006;53:245-56 (Pubitemid 44033922)
142. Schirrmacher E, Beck C, Brueckner B, et al. Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjug Chem 2006;17:261-6
143. Suzuki T, Tanaka R, Hamada S, et al. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg Med Chem Lett 2010;20:1124-7
144. Klisovic RB, Stock W, Cataland S, et al. A Phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 2008;14:2444-9 (Pubitemid 351551079)
145. Gore SD. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 2009;33(Suppl 2):S2-6
146. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632-42 (Pubitemid 41185132)
147. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005;114:683-95 (Pubitemid 40344429)
148. Giachelia M, D'Alo F, Fabiani E, et al. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. Leuk Res: published online 23 September 2010, doi:10.1016/j.leukres.2010.07.022
149. Scott SA, Pearson DS, Bainbridge MN, et al. cDNA Microarray Analysis of genes up-regulated by treatment with 5-AZA-2′-Deoxycytidine in combination with trichostatin a identifies aberrant metallothionein 1h promoter methylation at a high frequency iin human AML. ASH Annual Meeting Abstracts. Blood 2009;104:2036
150. Weber B, Kimhi S, Howard G, et al. Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene 2010;29:5775-84
151. Saito Y, Suzuki H, Tsugawa H, et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 2009;28:2738-44
152. Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008;13:496-506 (Pubitemid 351763902)
153. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005;33:1290-7 (Pubitemid 41439922)
154. Grovdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol 2010;150:293-302
155. Ettou S, Humbrecht C, Benet B, et al. FAS Gene expression is epigenetically regulated and predicts the responsiveness to azacitidine in high-risk myelodysplastic syndromes. ASH Annual Meeting Abstracts. Blood 2010;116:232
156. Follo MY, Mongiorgi S, Clissa C, et al. Epigenetic regulation of lipid signalling pathways in low-risk mds patients during azacitidine treatment. ASH Annual Meeting Abstracts. Blood 2010;116:233
157. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-42
158. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-7
159. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301
160. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-10
161. Mohamedali AM, Smith AE, Gaken J, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009;27:4002-6
162. Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009;114:3285-91
163. Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009;94:1676-81
164. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38
165. Lorsbach RB, Moore J, Mathew S, et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003;17:637-41 (Pubitemid 36395661)
166. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-5
167. Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010;466:1129-33
168. Pollyea DA, Raval A, Kusler B, et al. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol 2010; published online 27 October 2010, doi: 10.1002/hon.976
169. Richardson B. DNA methylation and autoimmune disease. Clin Immunol 2003;109:72-9 (Pubitemid 37324744)
170. Qin T, Jelinek J, Si J, et al. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 2009;113:659-67
171. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010;5:e9001: published online 2 February 2010, doi:10.1371/journal.pone.0009001
172. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer. 2010;116:1485-94
173. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011:published online 10 January 2011, doi:10.1002/cncr.25774